drugset / Trial / NCT00477451
Staccato Alprazolam in Panic Attack
RandomizedParallel-groupQuadruple-blindTreatment
Summary
We are developing Staccato™ Alprazolam for the treatment of Panic attacks associated with panic disorder. This study will provide an initial assessment of efficacy, and to continue to describe the tolerability and pharmacokinetics, of a single inhaled dose of Staccato Alprazolam on a doxapram-induced panic attack in patients with panic disorder.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alprazolam | Small molecule | 1 mg | Inhaled |
| Subject | Alprazolam | Small molecule | 2 mg | Inhaled |
| Background | Doxapram | Small molecule | 0.5 mg/kg | Intravenous |
Indications
No indication recorded.